scispace - formally typeset
Open AccessJournal ArticleDOI

Innovative preparation of curcumin for improved oral bioavailability.

TLDR
THERACURMIN exhibited an inhibitory action against alcohol intoxication after drinking in humans, as evidenced by the reduced acetaldehyde concentration of the blood, and shows a much higher bioavailability than currently available preparations.
Abstract
Curcumin is a polyphenol that is commonly used for its perceived health benefits. However, the absorption efficacy of curcumin is too low to exhibit beneficial effects. We have successfully developed a highly absorptive curcumin dispersed with colloidal nano-particles, and named it THERACURMIN. The absorption efficacy of THERACURMIN was investigated and compared with that of curcumin powder. The area under the blood concentration-time curve (AUC) after the oral administration of THERACURMIN was found to be more than 40-fold higher than that of curcumin powder in rats. Then, healthy human volunteers were administered orally 30 mg of THERACURMIN or curcumin powder. The AUC of THERACURMIN was 27-fold higher than that of curcumin powder. In addition, THERACURMIN exhibited an inhibitory action against alcohol intoxication after drinking in humans, as evidenced by the reduced acetaldehyde concentration of the blood. These findings demonstrate that THERACURMIN shows a much higher bioavailability than currently available preparations. Thus, THERACURMIN may be useful to exert clinical benefits in humans at a lower dosage.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials

TL;DR: Curcumin has shown protection against hepatic conditions, chronic arsenic exposure, and alcohol intoxication, and dose-escalating studies have indicated the safety of curcumin at doses as high as 12 g/day over 3 months.
Journal ArticleDOI

Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: The golden pigment from golden spice

TL;DR: How curcumin should be delivered in vivo, how bioavailable is it, how wellCurcumin is absorbed and how it is metabolized, is the focus of this review.
Journal ArticleDOI

Applications of nanoparticle systems in drug delivery technology

TL;DR: arget and sustained drug delivery decreases the drug related toxicity and increase patient’s compliance with less frequent dosing, also providing advancement in diagnostic testing.
Journal ArticleDOI

Curcumin nanoformulations : A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment

TL;DR: Recent works on the design and development of nano-sized delivery systems for curcumin, including liposomes, polymeric nanoparticles and micelles, conjugates, peptide carriers, cyclodextrins, solid dispersions, lipid nanoparticlesand emulsions are summarized.
Journal ArticleDOI

Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases

TL;DR: Curcumin, a yellow pigment in the Indian spice Turmeric (Curcuma longa), which is chemically known as diferuloylmethane, was first isolated exactly two centuries ago in 1815 by two German Scientists, Vogel and Pelletier.
References
More filters
Journal ArticleDOI

Bioavailability of curcumin: problems and promises.

TL;DR: Enhanced bioavailability of curcumin in the near future is likely to bring this promising natural product to the forefront of therapeutic agents for treatment of human disease.
Journal Article

Anticancer potential of curcumin: preclinical and clinical studies.

TL;DR: Evidence has also been presented to suggest that curcumin can suppress tumor initiation, promotion and metastasis, and Pharmacologically,Curcumin has been found to be safe.
Journal Article

Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.

TL;DR: It is demonstrated that curcumin is not toxic to humans up to 8,000 mg/day when taken by mouth for 3 months and a biologic effect ofCurcumin in the chemoprevention of cancer is suggested.
Journal ArticleDOI

Dose escalation of a curcuminoid formulation.

TL;DR: The tolerance of curcumin in high single oral doses appears to be excellent, and these findings warrant further investigation for its utility as a long-term chemopreventive agent.
Journal ArticleDOI

Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance

TL;DR: A daily oral dose of 3.6 g of curcumin is advocated for Phase II evaluation in the prevention or treatment of cancers outside the gastrointestinal tract in patients with advanced colorectal cancer refractory to standard chemotherapies.
Related Papers (5)